PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection
Sign Up to like & getrecommendations! Published in 2021 at "PLoS Pathogens"
DOI: 10.1371/journal.ppat.1009594
Abstract: PfSPZ-CVac combines ‘PfSPZ Challenge’, which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis. In a previously-published PfSPZ-CVac study, three doses of 5.12x104 PfSPZ-CVac given 28 days apart had 100% vaccine efficacy (VE)… read more here.
Keywords: malaria; pfspz; parasitemia; day ... See more keywords